title: [Lipids and AIDS].
abstract: HIV infection induces an early decrease of cholesterol and a late increase of triglycerides (TG) with a reduction of HDL. These changes are proportional with the lowering of CD4, which reflects the infection's severity. Both the increase of TG synthesis and the decrease of TG catabolism, in relation with a reduction of lipoprotein lipase activity, are responsible of these changes. Moreover, LDL catabolism is enhanced by macrophage scavenger receptors, due to a high proportion of small, dense LDL which are more easily oxidized. Many cytokines (interferon alpha, interleukins, TNF) play probably a pathogenic role in the dyslipidemia. Some HIV patients who received antiproteases may develop lipodystrophy with central obesity, insulino-resistance, glucose intolerance and sometimes diabetes (like in syndrome X). Other patients present a cushingoid, buffalo hump. This complication may be observed also with antiretroviral treatment other than antiproteases. The physiopathology of these findings could be in relation with structural homologies between antiproteases and some important proteins, involved in lipid and adipocyte metabolism. Cardiovascular risk linked to these perturbations is evident. The treatment is not different from the treatment for seronegative, hyperlipidemic patients: struggle against risk factors, diet advices, fibrates or statins. The antiproteases bring huge contribution to the prognosis of AIDS patients but the risk of cardiovascular complications could impair this therapeutic progress. So, it is essential to understand the pathogeny of these complications in order to discover new antiproteases, without these adverse side effects.
authors.affiliation: Services de Médecine, C.H.U. Tivoli, La Louvière.
authors.forename: J
authors.initials: J
authors.lastname: Ducobu
authors.forename: M C
authors.initials: MC
authors.lastname: Payen
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000097:blood* / Q000188:drug therapy; D017667:Adipocytes / Q000187:drug effects / Q000378:metabolism; D018791:CD4 Lymphocyte Count; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D016207:Cytokines / Q000097:blood; D003920:Diabetes Mellitus / Q000139:chemically induced; D018149:Glucose Intolerance / Q000139:chemically induced; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006331:Heart Diseases / Q000209:etiology; D006801:Humans; D015228:Hypertriglyceridemia / Q000097:blood; D007009:Hypolipoproteinemias / Q000097:blood; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood*; D008060:Lipodystrophy / Q000139:chemically induced; D009765:Obesity / Q000139:chemically induced; D011379:Prognosis; D012307:Risk Factors
chemical_list: D008076:Cholesterol, HDL; D016207:Cytokines; D017320:HIV Protease Inhibitors; D008055:Lipids; D002784:Cholesterol